Echoing the 12 Days of Christmas, this festive guide outlines the seasonal risks clinicians can help patients avoid. Medscape News UK
Aflibercept 8 mg Promising Alternative to 2 mg for PCV
Aflibercept 8 mg provides similar outcomes for vision and eye structure as the 2-mg dose in patients with polypoidal choroidal vasculopathy, a recent study finds. Medscape Medical News
GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Uncategorized
Thyroid Eye Disease (TED) Treatments Market Nears $4.3 Billion by 2032: Emerging Small Molecule Therapies Targeting Orbital Fibroblasts Drive Revenue Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Thyroid Eye Disease Treatments Market – Global Forecast 2025-2032” report has been added to ResearchAndMarkets.com’s offering. The thyroid eye disease treatments market is undergoing substantial transformation, fueled by n…
Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today responded to the fourth po…
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right under the Alcon merger agreement to require STAAR t…